GlassScriptPhysician profile
Charles J Frankel
NPI 1558310805
$3,490.66
in general payments reported to CMS, 2019-2025
24 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $194 · 2021: $390 · 2022: $687 · 2023: $587 · 2024: $711 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.52 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.38 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $493.05 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $336.36 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $193.60 | 2019-2023 | Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $189.36 | 2019-2023 | Entyvio |
| Genzyme Corporation | $176.02 | 2022-2024 | |
| Pfizer INC. | $155.63 | 2019-2025 | |
| Janssen Biotech, INC. | $131.36 | 2019-2024 | Stelara |
| Intercept Pharmaceuticals, INC. | $97.73 | 2019-2023 | Ocaliva |
| Ardelyx, INC. | $95.37 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $84.93 | 2023-2024 | Dupixent |
| Madrigal Pharmaceuticals | $81.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $74.80 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $55.65 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $47.76 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $37.75 | 2021-2024 | |
| Amgen INC. | $34.75 | 2022 | |
| Gilead Sciences, INC. | $33.31 | 2021 | |
| Allergan, INC. | $32.15 | 2019 | |
| Ferring Pharmaceuticals INC. | $23.95 | 2019 | |
| Lilly USA, LLC | $21.52 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $21.32 | 2024 | Bylvay |
| Qol Medical, LLC | $16.79 | 2021 | |
| Romark Laboratories, Lc | $9.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Frankel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.